CoChat

Molecular targeting of Alzheimer's amyloid plaques for contrast‐enhanced magnetic resonance imaging

Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., Jack, C. R. · 2002 · Journal of Neurochemistry
Cited by 43

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide quantum advances in clinical medicine and biomedical research. We describe such a probe that targets amyloid plaques of Alzheimer's disease and has been labelled with gadolinium to impart contrast detectable by magnetic resonance imaging. Although amyloid plaques are a primary pathologic feature of Alzheimer's disease and amyloid reduction is a major therapeutic objective in Alzheimer's disease, no method currently exists for directly imaging human amyloid plaques in vivo. However, with the aid of a target specific contrast agent, imaging of amyloid plaques is theoretically possible with magnetic resonance imaging. We describe experiments proving that three essential properties exist in the smart molecular probe, putrescine‐gadolinium‐AB peptide: (1) transport across the blood–brain barrier following intravenous injection conferred by the polyamine moiety (2) binding to plaques with high affinity by putrescine‐AB, and (3) magnetic resonance imaging contrast by gadolinium. The plaque‐to‐background tissue contrast‐to‐noise ratio was enhanced more than 9 fold in all regions of cortex and hippocampus following intravenous administration of putrescine‐gadolinium‐AB in Alzheimer's disease transgenic mice. The ability of this magnetic resonance contrast probe to image plaques in vivo may enable early diagnosis and also provide a direct measure of the efficacy of antiamyloid therapies currently being developed. With the appropriate target specific probe (e.g. antibody), this technique could be applied to many other central nervous system disorders and targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.81.s1.20_5.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 43

Metadata

Authors
Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., & Jack, C. R.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2002-06
Volume
81
Issue
s1
Pages
60-63
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1975023072
Cited by
43
References
1
FWCI
1.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular targeting of Alzheimer's amyloid plaques for contrast‐enhanced magnetic resonance imaging. https://app.cochat.ai/papers/10.1046/j.1471-4159.81.s1.20_5.x
The paper
Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., & Jack, C. R. (2002). Molecular targeting of Alzheimer's amyloid plaques for contrast‐enhanced magnetic resonance imaging. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.81.s1.20_5.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.